BlueRock – a Bayer subsidiary – is currently evaluating the pluripotent stem cell-derived dopaminergic neuron therapy in a phase 1 study.
This early-stage trial is set to enrol ten patients across the US and Canada, with its primary objective to assess the safety and tolerability of DA01 cell transplantation at one-year post-transplant.
As a secondary objective, BlueRock will assess the evidence of transplanted cell survival and motor effects at one- and two-years post-transplant and evaluate the continued safety and tolerability at two years, as well as the feasibility of transplantation.
